ARK Clears Teradyne From Flagship Fund as Stock Rallies on AI Test Demand

Cathie Wood's ARK Innovation ETF (NYSEARCA:ARKK) sold its final Teradyne (NASDAQ:TER) shares on Wednesday, November 11, 2026. ARK's daily trade file valued the last sale at roughly $110,300 and flagged it as 100% of the fund's position.

The bulk of the exit came a day earlier. On November 10, the trade file showed ARKK selling about $1.4 million of Teradyne, equal to 95.09% of its stake. The November 11 holdings file listed 415 shares worth $101,841 before the final trade cleared them out. ARK gave no reason for the sales. Neither Wood nor the firm posted an explanation on X or elsewhere, so any motive, including timing the rally, remains speculation.

The stock moved the other way. Teradyne rose 8.30% to $265.78 on November 11, the same day Jefferies initiated coverage at Buy with a $284 price target. After hours, the shares slid 2.75% to $258.48.

What do the trade files actually show?

ARK still owns Teradyne through a second fund. The ARK Autonomous Technology and Robotics ETF (NYSEARCA:ARKQ) held 231,809 shares worth $56.9 million, a 3.32% portfolio weight, in its November 11 filing. At the close, that stake was worth about $61.6 million.

Both ARKK sales are negligible against Teradyne's $41.49 billion market capitalization. They describe one fund's holdings. They say nothing about the underlying business.

The business itself is running hot. Teradyne builds automated test equipment, the machines that verify chips before shipment, and it operates a robotics unit. AI processors and high-bandwidth memory require more testing, and test's share of chip capital spending rose from 6.4% in 2025 to 8.1% for the first eight months of 2026.

Third-quarter revenue exceeded $1.3 billion, up 70% year over year, and non-GAAP EPS of $2.29 beat expectations. Management said: "AI-driven revenue represents more than 60% of total revenue."

Why did two ARK funds treat the same stock differently?

The mandates diverge. ARKK targets broad disruptive innovation, and a dividend-paying equipment maker worth tens of billions no longer resembles an early-stage holding. ARKQ's automation focus fits Teradyne's robotics arm, which reached profitability in the third quarter.

ARKK's money moved elsewhere on November 11. ARKK and ARKQ together added about $3.1 million of Kratos Defense (NASDAQ:KTOS), while ARK's genomics fund bought roughly $7.5 million of Prime Medicine (NASDAQ:PRME). Other ARK funds purchased space and air-mobility names.

The stock's recent path explains some of the churn. Teradyne closed at a record $483.84 on June 30, then fell to $212.74 by November 5, including a 15.24% drop that day. It remains down 30.76% over the past month. Since the November 5 low, the stock has rallied about 25%, but it still trades far below its June record.

Chip-equipment spending runs in cycles, and Teradyne's biggest new computing programs depend on a handful of hyperscaler and GPU customers whose ramps are expected in 2027.

What could move TER stock after ARK's exit?

Guidance points upward for now. Management guided fourth-quarter revenue of $1,250 million to $1,350 million and expects 2027 to deliver another year of healthy growth.

The cost is volatility. A 12.73% gain on November 9 shows how far the stock can move in a single session.

Two checks will test the post-exit picture. First, watch whether ARKQ's daily file starts cutting its 231,809-share position. Second, watch whether Teradyne holds above its $212.74 November 5 close heading into the fourth-quarter earnings call, where management plans to provide an updated model — a close below that level would signal that the market doubts AI test demand more than the reported results do.